Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma

Neha Mehta-Shah, Anas Younes

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma. Next-generation sequencing techniques have improved our understanding of the molecular pathways that may drive oncogenesis. Many novel classes of drugs are in development that may improve the treatment of DLBCL, either as single agents or in combination, that exploit their synergy to overcome resistance. We review the key novel targets and therapeutics in the treatment of DLBCL, including immunomodulatory agents and immunotherapy.

Original languageEnglish
Pages (from-to)126-137
Number of pages12
JournalSeminars in Hematology
Issue number2
StatePublished - Apr 1 2015


Dive into the research topics of 'Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma'. Together they form a unique fingerprint.

Cite this